Erasca, Inc. (ERAS)

Market Cap	3.14B
Revenue (ttm)	n/a
Net Income	-127.69M
EPS	-0.45
Shares Out	309.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,026,577
Open	10.69
Previous Close	10.50
Day's Range	9.89 - 10.71
52-Week Range	1.01 - 10.71
Beta	1.15
Analysts	Strong Buy
Price Target	5.78 (-43.05%)
Earnings Date	Mar 19, 2026

About ERAS

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 16, 2021
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: ERAS
• Website: https://www.erasca.com

Analyst Summary

According to 9 analysts, the average rating for ERAS stock is "Strong Buy." The 12-month stock price target is $5.78, which is a decrease of -43.05% from the latest price.

Price Target

$5.78

(-43.05% downside)

Analyst Consensus: Strong Buy